BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 29105142)

  • 1. The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines.
    Bahi M; Walmsley RS; Gray AR; Young D; Hobbs CE; Aluzaite K; Schultz M
    J Gastroenterol Hepatol; 2018 May; 33(5):1047-1052. PubMed ID: 29105142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature.
    Hagen JW; Pugliano-Mauro MA
    Dermatol Surg; 2018 Apr; 44(4):469-480. PubMed ID: 29315147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
    Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
    Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
    Long MD; Martin CF; Pipkin CA; Herfarth HH; Sandler RS; Kappelman MD
    Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.
    Long MD; Herfarth HH; Pipkin CA; Porter CQ; Sandler RS; Kappelman MD
    Clin Gastroenterol Hepatol; 2010 Mar; 8(3):268-74. PubMed ID: 20005977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort.
    Abbas AM; Almukhtar RM; Loftus EV; Lichtenstein GR; Khan N
    Am J Gastroenterol; 2014 Nov; 109(11):1781-93. PubMed ID: 25244964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis.
    Ariyaratnam J; Subramanian V
    Am J Gastroenterol; 2014 Feb; 109(2):163-9. PubMed ID: 24419479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
    Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
    JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis.
    Huang SZ; Liu ZC; Liao WX; Wei JX; Huang XW; Yang C; Xia YH; Li L; Ye C; Dai SX
    J Gastroenterol Hepatol; 2019 Mar; 34(3):507-516. PubMed ID: 30393891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study.
    Setshedi M; Epstein D; Winter TA; Myer L; Watermeyer G; Hift R
    J Gastroenterol Hepatol; 2012 Feb; 27(2):385-9. PubMed ID: 21793904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study.
    Clowry J; Sheridan J; Healy R; Deady S; Keegan D; Byrne K; Cullen G; Mulcahy H; Comber H; Parnell AC; Doherty G; Lally A
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):978-985. PubMed ID: 28045204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
    Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
    World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
    Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
    Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks of Melanoma and Nonmelanoma Skin Cancers Pre- and Post-Inflammatory Bowel Disease Diagnosis.
    Narous M; Nugent Z; Singh H; Bernstein CN
    Inflamm Bowel Dis; 2023 Jul; 29(7):1047-1056. PubMed ID: 35929649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
    McKenna MR; Stobaugh DJ; Deepak P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antenatal thiopurine exposure in women with IBD is associated with intrahepatic cholestasis of pregnancy.
    Selinger CP; Rosiou K; Broglio G; Lever G; Chiu CM; Stocker LJ; Chipeta H; Glanville T
    Expert Opin Drug Saf; 2023; 22(11):1091-1097. PubMed ID: 37417244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.
    Moran GW; Lim AW; Bailey JL; Dubeau MF; Leung Y; Devlin SM; Novak K; Kaplan GG; Iacucci M; Seow C; Martin L; Panaccione R; Ghosh S
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1002-24. PubMed ID: 24099467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease.
    Singh H; Nugent Z; Demers AA; Bernstein CN
    Gastroenterology; 2011 Nov; 141(5):1612-20. PubMed ID: 21806945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Level of UV Exposure, Skin Type, and Age Are More Important than Thiopurine Use for Keratinocyte Carcinoma Development in IBD Patients.
    Wu Y; Ghaly S; Kerr S; Jackson B; Hanigan K; Martins D; Krishnaprasad K; Mountifield RE; Whiteman DC; Bampton PA; Gearry RB; Radford-Smith GL; Lawrance IC
    Dig Dis Sci; 2020 Apr; 65(4):1172-1179. PubMed ID: 31493039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.